Christophe De Romeuf

This inventor holds 30 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Lfb Biotechnologies, Centre National De La Recherche Scientifique. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christophe De Romeuf. Retrieved from https://idiyas.com/inventor/christophe-de-romeuf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 12)

% Patents Active = 46.7

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 18 (Patent Applications = 24)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 120(Granted Patents)

Location History:

Lille, FR (2009 - 2018)
Lambersart, FR (2009 - 2023)

Company Filing History:

21 out of 97

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Centre National De La Recherche Scientifique

patents

4. 2 out of 55

Université De Limoges

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Chimeric Protein

Monoclonal Antibodies

Immunotherapy

ADCC Optimization

Fc Fragments

CD20 Antigen

Recombinant Antibodies

Humanized Antibodies

Cancer Treatment

Amyloidosis

CD303 Antigen

Effector Cells

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12291552 - Chimeric protein in the treatment of amyloidosis (2025-05-06),

2. 12247076 - Use of modified Fc fragments in immunotherapy (2025-03-11),

3. 11649271 - Fc mutants with modified functional activity (2023-05-16),

4. 11345730 - Chimeric protein in the treatment of amyloidosis (2022-05-31),

5. 10611843 - Anti-CD303 monoclonal antibodies (2020-04-07),

6. 10239946 - Cell line overexpressing human CD303 antigen (2019-03-26),

7. 10081683 - Monoclonal antibodies with enhanced ADCC function (2018-09-25),

8. 9879089 - Use of ADCC-optimized antibodies for treating low-responder patients (2018-01-30),

9. 9873745 - Antibody method for treatment of a disease in which the target cells are cells which express CD20 (2018-01-23),

10. 9718890 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

11. 9718889 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

12. 9708409 - Monoclonal antibodies with enhanced ADCC function (2017-07-18),

13. 9546217 - Recombinant anti-MUC1 antibodies (2017-01-17),

14. 9234045 - Monoclonal antibody directed against CD20 antigen (2016-01-12),

15. 9109020 - Use of ADCC-optimized antibodies for treating weak patients (2015-08-18),

Title: The Innovative Contributions of Christophe De Romeuf in Immunotherapy

Introduction

Christophe De Romeuf, based in Lambersart, France, is an accomplished inventor renowned for his contributions to the field of immunotherapy. With an impressive portfolio of 29 patents, De Romeuf has made significant strides in enhancing therapeutic approaches for autoimmune and inflammatory diseases.

Latest Patents

Among his latest innovations are two notable patents that demonstrate his expertise. The first patent focuses on the "Use of modified Fc fragments in immunotherapy," exploring the application of isolated recombinant Fc fragments with modified affinity to Fc receptors (FcR). These advancements hold promise for the effective treatment of autoimmune and inflammatory conditions. His second patent, titled "Fc mutants with modified functional activity," introduces polypeptides with mutated Fc regions exhibiting altered functional activities. This innovation involves specific combinations of mutations that enhance the polypeptide's capabilities, offering valuable insights for further therapeutic developments.

Career Highlights

Christophe De Romeuf's professional journey includes significant roles at leading biotechnology companies, including Laboratoire Français Du Fractionnement Et Des Biotechnologies and LFB Biotechnologies. His tenure at these organizations has allowed him to contribute to groundbreaking research and development in immunotherapeutic solutions.

Collaborations

Throughout his career, De Romeuf has collaborated with esteemed colleagues, including Dominique Bourel and Nicolas Bihoreau. These partnerships have enriched his research endeavors, fostering a collaborative environment that encourages innovation and discovery in the biotechnology sector.

Conclusion

In summary, Christophe De Romeuf stands out as a prolific inventor whose work in immunotherapy has the potential to revolutionize treatment strategies for autoimmune and inflammatory diseases. His impressive array of patents reflects a commitment to enhancing patient outcomes through innovative approaches, solidifying his legacy in the field of biotechnology.

Profile summary based on public USPTO records.